Chronic lymphocytic leukemia (CLL) comprises 2 subsets, distinguished by expression of unmutated or mutated VHgenes, with the former having a worse prognosis. Biased usage of the V1-69 gene is found in unmutated cases and is combined with selected D gene segments and JH6. It is controversial whether this is a CLL-associated feature or mirrors the normal B-cell pattern. Since CLL is a disease of the elderly, where changes in the B-cell repertoire may occur, we have analyzedV1-69 usage in the elderly (older than 75 years) population. Using monoclonal antibody (MoAb) G6, specific for 51p1-related V1-69 alleles, we found no increased expression with age. In 51p1-encoded immunoglobulin M (IgM), complementarity-determining region 3 (CDR3) length and frequency of D and JH genes were similar to those in the healthy young and distinct from those in CLL. These findings support the concept that CLL arises from B cells driven by antigen/superantigen and is not a stochastic event in the elderly B-cell population.

Analysis of morphology, immunophenotype, and gene expression of cases of chronic lymphocytic leukemia (CLL) has indicated considerable disease homogeneity.1,2 However, investigation of the clonal immunoglobulin V gene sequences has revealed 2 subsets, derived from B cells either before or after somatic mutation.3-6 Since there is a powerful prognostic difference between the 2 subsets, with the unmutated being worse,5-7 insight into the pathogenesis of each may be relevant for understanding malignant behavior.

CLL was known to show biased usage of the V1-69 gene segment, ranging from 10% to 21%,3-11 and this lies within the unmutated subset.3-5 In contrast, bias to other VH genes, including V4-34, lies in the mutated subset.3-5 Since bias may reflect response to a superantigen,12 these differences point to distinct influences on pathogenesis of the subsets.

The 51p1-related subset of the V1-69 locus is frequently expressed in CLL5,7,11 and, in that setting, is commonly associated with D3-3 and D3-10 genes,JH6, and a long complementarity-determining region 3 (CDR3).5,8 There is controversy as to whether these features are disease-associated8,13 or simply reflect the pattern of usage in normal B cells.9Comparisons have generally been made with the healthy adult repertoire derived from relatively young individuals.9,13 However, CLL presents at a mean age of approximately 60 years, and the B-cell repertoire may change with age.14,15 Asymmetries in VH gene usage could contribute a stochastic element to the pattern in CLL. To resolve this question, we have investigated expression of the 51p1 gene in a healthy elderly population (older than 75 years) using monoclonal antibody G6 (MoAb G6).16 We have also analyzed51p1-derived sequences from the immunoglobulin M (IgM) of B cells of 4 elderly individuals.

Immunophenotypic analysis of healthy elderly and young adult blood lymphocytes

Blood was obtained from 35 young (younger than 35 years; 17 male, 18 female) and 42 elderly individuals (older than 75 years; 14 male, 28 female). Subjects were excluded if they had a history of lymphoproliferative disease, acute infection, or autoimmune disease or if they were taking immunosuppressive agents. The MoAb G6 was used to determine the frequency of 51p1-related alleles.16 G6 reacts with an idiotypic determinant derived from CDR2 in the five 51p1-like alleles, but not in the 8 hv1263-like variants at theV1-69 locus.11,17 18 Peripheral blood mononuclear cells (PBMCs) were stained with G6 followed by sheep antimouse–fluorescein isothiocyanate (FITC) and subsequently with CD5-phycoerythrin (PE)/CD19–R-phycoerythrin (RPE)–cyanin 5(Cy5) (Dako, Glostrup, Denmark). Red cells were lysed (FACSLyse; BD, Cowley, Oxford, United Kingdom), and an initial 900 000 cells were acquired in a BD Facscalibur flow cytometer.

Analysis of 51p1 gene sequences

VH51p1-encoded genes were amplified by touchdown polymerase chain reaction (PCR) (QIAGEN, Crawley, United Kingdom) of cDNA from PBMCs from 4 elderly individuals by means of a 51p1-variant CDR2-specific primer13 and a Cμ primer.19Gel-purified PCR products were cloned in pGEM T-vector (Promega, Southampton, United Kingdom). The 26 sequences determined in this study can be found in GenBank under accession numbers AY179836-AY179861. Twelve sequences from 5 healthy elderly subjects all 65 years or older14 were added to those in this study. Included were 44 sequences from CLL patients4,5,8 and 44 from healthy young adults9 13 expressing unmutated51p1-related IgM.

The 35 young and 42 elderly individuals had similar B-cell numbers, and percentages of CD5+ B cells (20.5% and 16.7%, respectively). G6 expression correlates with the germ-line copy number of 51p1-related genes and is absent in approximately 11% of healthy individuals (Sasso et al20). A wide range of G6+ B cells was found in both groups (Figure 1), with 1% to 12.6% (mean, 4.7% ± 0.45%) in the young and 1% to 10% (mean, 4.3% ± 0.44%) in the elderly, and approximately 10% of both cohorts being G6. Mean levels are higher than a previous report (1.7%), probably owing to low numbers (7 individuals) studied (Shokri et al21). Heterogeneity in expression ofV1-69 in healthy people was also found by means of IgM cDNA libraries and single-cell analysis.14 That study pointed to a possible increased expression in the elderly (older than 65 years) (6%) as compared with the young (0.8%). However, libraries from only 5 elderly individuals were assessed, again a small sample. Clearly, although there is a reported dysregulation of B-cell responses in older populations of both humans15 and mice,22probably owing to failing T-cell help, this does not affect the number of IgM+51p1-expressing B cells.

Fig. 1.

Percentages of G6+ B cells in the peripheral blood.

(A) Peripheral blood was stained with mouse MoAb G6 followed by sheep antimouse-FITC and subsequently with CD5-PE/CD19-RPE-Cy5. On an initial 10 000-cell acquisition, the B cells were defined as shown by the gates R1 (lymphocytes) and R2 (CD19+ lymphocytes). Approximately 900 000 total events per tube were acquired in an R1-plus-R2 live gate to give percentages for G6 reactivity. (B) Comparison of the percentage of G6+ lymphocytes in 35 young (▪) and 42 (▴) elderly individuals.

Fig. 1.

Percentages of G6+ B cells in the peripheral blood.

(A) Peripheral blood was stained with mouse MoAb G6 followed by sheep antimouse-FITC and subsequently with CD5-PE/CD19-RPE-Cy5. On an initial 10 000-cell acquisition, the B cells were defined as shown by the gates R1 (lymphocytes) and R2 (CD19+ lymphocytes). Approximately 900 000 total events per tube were acquired in an R1-plus-R2 live gate to give percentages for G6 reactivity. (B) Comparison of the percentage of G6+ lymphocytes in 35 young (▪) and 42 (▴) elderly individuals.

Close modal

Sequence analysis of the available CDR2–framework region 4 (FR4) regions of the 51p1-related genes from the G6+ elderly group revealed all to be unmutated. A previous study of one individual from a cohort of healthy laboratory volunteers and blood donors, assumed to be younger than 60 years, had found heterogeneity of CDR3 length (mean, 14.6 ± 4.3 codons); use of a range of D genes; and frequent use of JH4 andJH6.13 These, compiled with a further 6 sequences from “healthy young”9 individuals (Figure 2A) are clearly different from cases of CLL that have a longer CDR3 (mean, 19.3 ± 3.5 codons) and common involvement of JH6.4,5 8Superimposition of the sequence data from the elderly cohort indicates a length distribution (mean, 16.6 ± 3.5 codons) similar to that of the young group (mean, 15.1 ± 4.1 codons; P = .074), and distinct from CLL sequences (mean, 19.3 ± 3.5 codons;P = .0009) (Figure 2A). In fact, both healthy groups appear heterogeneous in length, with a possibility of 2 subsets of long and short sequence. Although numbers are small, the subsets with longer CDR3 appear to overlap the major fraction of CLL sequences.

Fig. 2.

Comparison of V1-69 (51p1) CDR3 length distribution and associated JH and D gene segments in healthy young people, healthy elderly people, and cases of CLL.

(A) CDR3 length distribution. (B) JH gene segment usage. (C) D gene segment usage. Unk indicates unknown.

Fig. 2.

Comparison of V1-69 (51p1) CDR3 length distribution and associated JH and D gene segments in healthy young people, healthy elderly people, and cases of CLL.

(A) CDR3 length distribution. (B) JH gene segment usage. (C) D gene segment usage. Unk indicates unknown.

Close modal

The CDR3 sequence includes JH-derived amino acids, and involvement of JH6 often leads to a longer CDR3.13 Analysis of JH genes combined with the51p1 gene in the elderly shows JH4 to be most common (Figure 2B), further distinguishing normal B cells from CLL, where JH6 is preferred.4,5,8The young cohort is again similar to the elderly, apart from a higher use of JH6 in the former. In the 22 sequences that have a CDR3 of 17 or fewer amino acids, only 4 (18.2%) useJH6. In contrast, in the 16 sequences in which the CDR3 had 18 or more amino acids, 7 (43.8%) useJH6. Therefore, there appears to be an association, although not complete, between JH6usage and longer CDR3 sequences, as indicated previously.13 

The D gene segment was identified in the elderly cohort for 26 of 38 sequences. Figure 2C indicates that the D3 (8 of 38) and D2 (8 of 38) families were the most frequently used. The young frequently used the D6 and D3 families, with both frequently using D3-22. In contrast, CLL sequences have a strikingly common use ofD3-3, followed by D3-10 (Figure2C).4,5,8 In cases of CLL involving D3-3, 8 of 13 tend to have CDR3 derived from the second reading frame with the motif (Y)DFWSGY(Y)(P).13 Since selection of D3-3 is not a feature of normal B cells in either young or elderly repertoires, this may be a disease-associated feature. However, other sequence motifs evident in51p1-encoded CLL may not be disease-associated. Thus, a motif encoded by the third (hydrophobic) reading frame of theD2-2 gene (VVPAA), found frequently in CLL, was also found in 2 of the D2-2–derived sequences in the elderly group. Interestingly, this was rare in the young 51p1repertoire.13 

Bias to 51p1 together with selected CDR3 sequences points to a role for antigen/superantigen in driving the cell of origin of this subset of unmutated CLL. We found no evidence for an expanded pool of B cells accumulating with age that would act as precursors for transformation. Although dysregulation of immunity occurs in the elderly, with emergence of endogenous viruses23 and increasing autoreactivity,15 perturbation apparently does not occur in 51p1-encoded immunoglobulin. This supports the concept that development of CLL is not a simple stochastic event, but derives from cells driven by specific antigens, some of which are recognized by 51p1-encoded IgM. If antigen is persistent, as for certain pathogens, or autoantigens, it could contribute to tumor growth via surface IgM (sIgM)–mediated signals, known to be transmitted in the unmutated subset.2 24 

We acknowledge Gavin Babbage for DNA sequencing. We are grateful to Professor Roy Jefferis (University of Birmingham Medical School, Birmingham, United Kingdom) for the kind gift of monoclonal antibody G6.

Prepublished online as Blood First Edition Paper, December 12, 2002; DOI 10.1182/blood-2002-08-2432.

Supported by Tenovus, United Kingdom.

K.N.P. and J.O. contributed equally to this work.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Klein
 
U
Yuhai
 
T
Stolovitzky
 
GA
et al
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.
J Exp Med.
194
2001
1625
1638
2
Rosenwald
 
A
Alizadeh
 
AA
Widhopf
 
G
et al
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.
J Exp Med.
194
2001
1639
1647
3
Schroeder
 
HW
Dighiero
 
G
The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire.
Immunol Today.
15
1994
288
294
4
Fais
 
F
Ghiotto
 
F
Hashimoto
 
S
et al
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.
J Clin Invest.
102
1998
1515
1525
5
Hamblin
 
TJ
Davis
 
Z
Gardiner
 
A
Oscier
 
DG
Stevenson
 
FK
Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Blood.
94
1999
1848
1854
6
Damle
 
RN
Wasil
 
T
Fais
 
F
et al
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Blood.
94
1999
1840
1847
7
Hamblin
 
TJ
Orchard
 
JA
Ibbotson
 
R
et al
CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.
Blood.
99
2002
1023
1029
8
Johnson
 
TA
Rassenti
 
LZ
Kipps
 
TJ
Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features.
J Immunol.
158
1997
235
246
9
Brezinschek
 
HP
Brezinschek
 
RI
Dorner
 
T
Lipsky
 
PE
Similar characteristics of the CDR3 of V(H)1-69/DP-10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells.
Br J Haematol.
102
1998
516
521
10
Rosenquist
 
R
Lindstrom
 
A
Holmberg
 
D
Lindh
 
J
Roos
 
G
V(H) gene family utilization in different B-cell lymphoma subgroups.
Eur J Haematol.
62
1999
123
128
11
Kipps
 
TJ
Tomhave
 
JE
Pratt
 
LF
Duffy
 
S
Chen
 
PP
Carson
 
DA
Developmentally restricted VH gene expressed at high frequency in chronic lymphoctyic leukemia.
Proc Natl Acad Sci U S A.
86
1989
5913
5917
12
Goodlick
 
L
Braun
 
J
Revenge of the microbes: superantigens of the T and B cell lineage.
Am J Pathol.
144
1994
623
636
13
Widhopf
 
GF
Kipps
 
TJ
Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells.
J Immunol.
166
2001
95
102
14
Wang
 
X
Stollar
 
BD
Immunoglobulin VH gene expression in human aging.
Clin Immunol.
93
1999
132
142
15
Weksler
 
ME
Changes in the B-cell repertoire with age.
Vaccine.
18
2000
1624
1628
16
Mageed
 
RA
Dearlove
 
M
Goodall
 
DM
Jefferis
 
R
Immunogenic and antigenic epitopes of immunoglobulins XVII: monoclonal antibodies reactive with common and restricted idiotopes to the heavy chain of human rheumatoid factors.
Rheumatol Int.
6
1986
179
183
17
Potter
 
KN
Mageed
 
RA
Jefferis
 
R
Capra
 
JD
Molecular characterization of the VH1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8.
Scand J Immunol.
50
1999
14
20
18
Sasso
 
EH
Willems van Dijk
 
K
Bull
 
AP
Milner
 
ECB
A fetally expressed immunoglobulin VH1 gene belongs to a complex set of alleles.
J Clin Invest.
91
1993
2358
2367
19
Chapman
 
CJ
Spellerberg
 
MB
Smith
 
GA
Carter
 
SJ
Hamblin
 
TJ
Stevenson
 
FK
Autoanti-red cell antibodies synthesized by patients with infectious mononucleosis utilize the VH4–21 gene segment.
J Immunol.
151
1993
1051
1061
20
Sasso
 
EH
Johnson
 
T
Kipps
 
TJ
Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number.
J Clin Invest.
97
1996
2074
2080
21
Shokri
 
F
Mageed
 
RA
Richardson
 
P
Jefferis
 
R
Modulation and high frequency expression of autoantibody-associated cross-reactive idiotypes linked to the VH1 subgroup in CD5-expressing B lymphycytes from patients with chronic lymphocytic leukaemia (B-CLL).
Scand J Immunol.
37
1993
673
679
22
Johnson
 
SA
Rozzo
 
SJ
Cambier
 
JC
Aging-dependent exclusion of antigen-inexperienced cells from the peripheral B cell repertoire.
J Immunol.
168
2002
5014
5023
23
Babcock
 
GJ
Decker
 
LL
Freeman
 
RB
Thorley-Lawson
 
DA
Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients.
J Exp Med.
190
1999
567
576
24
Lanham
 
S
Hamblin
 
T
Oscier
 
D
Ibbotson
 
R
Stevenson
 
F
Packham
 
G
Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphoctytic leukemia.
Blood.
101
2003
1087
1093

Author notes

Kathleen N. Potter, Tenovus Laboratory, Tremona Rd, Southampton University Hospitals Trust, Southampton, SO16 6YD, United Kingdom; e-mail: kp1@soton.ac.uk.

Sign in via your Institution